advanced search

INJECTION

HOW DIGITAL MEDICAL DEVICES ARE MEETING THE CHALLENGES OF CLINICAL TRIALS
CONNECTIVITY
Josh Hopkins
Noble
HOW DIGITAL MEDICAL DEVICES ARE MEETING THE CHALLENGES OF CLINICAL TRIALS
Josh Hopkins discusses the challenges that have been present in conducting clinical trials at a central brick-and-mortar location since their inception, and how modern digitisation presents an opportunity to improve clinical trial methodology by liberating it from the need for an in-person central study site via the use of digital medical devices and technologies.
SPECIALTY LCP COMPOUNDS FOR ELECTRONICS INTEGRATION IN CONNECTED MEDICAL DEVICES
CONNECTIVITY
Dr Young Kim
Celanese
SPECIALTY LCP COMPOUNDS FOR ELECTRONICS INTEGRATION IN CONNECTED MEDICAL DEVICES
Young Kim, Don DeMello and Philip Wilson, discuss the benefits of recent advances in liquid crystal polymer for connected medical devices.
ENSURING FUNCTIONAL PERFORMANCE AND REGULATORY COMPLIANCE OF ELASTOMER STOPPERS FOR MULTIPIERCING SITUATIONS
INJECTION
Bruno Morchain
Aptar Pharma
ENSURING FUNCTIONAL PERFORMANCE AND REGULATORY COMPLIANCE OF ELASTOMER STOPPERS FOR MULTIPIERCING SITUATIONS
Bruno Morchain, Sébastien Cordier and Estelle Verger discuss a series of experiments conducted on Aptar Pharma’s PremiumCoat® vial stoppers to demonstrate their compliance with EU and US Pharmacopeia standards and their excellent performance in multipiercing situations
FROM PROCESS TO PRODUCT: OPTIMISING PROCESS DEVELOPMENT STRATEGIES FOR VARIABLE DRUG-DEVICE REQUIREMENTS
INJECTION
Markus Goldinger
SHL Medical
FROM PROCESS TO PRODUCT: OPTIMISING PROCESS DEVELOPMENT STRATEGIES FOR VARIABLE DRUG-DEVICE REQUIREMENTS
Markus Goldinger and Erik Alexandersson discuss the benefits to process development provided by SHL’s fully in-house, vertically integrated model, and how those benefits are applied throughout the process from initial design work to final assembly of the drug delivery device and primary container.
TOWARDS USER-CENTRIC SPECIFICATION OF AUTOINJECTOR TECHNICAL ATTRIBUTES: INSIGHTS FROM EMPIRICAL WORK
INJECTION
Dr Andreas Schneider
Ypsomed
TOWARDS USER-CENTRIC SPECIFICATION OF AUTOINJECTOR TECHNICAL ATTRIBUTES: INSIGHTS FROM EMPIRICAL WORK
Andreas Schneider discusses an empirical study into both users’ ability to remove the cap from an autoinjector and the difficulty those patients perceived in doing so. The study builds a quantitative model relating the empirical data to patient perception.
DRIVERS FOR CHANGE IN ASEPTIC AUTOMATION
INJECTION
Dr Dave Seaward
3P Innovation
DRIVERS FOR CHANGE IN ASEPTIC AUTOMATION
Dave Seaward and David Phasey discuss the factors that have led to recent growth in aseptic automation within the pharmaceutical industry.
HOW TO ENSURE THE FUTURE DEMAND FOR BIOLOGICS CAN STILL BE DELIVERED BY INJECTABLES
INJECTION
Anthony Vico
Stevanato Group
HOW TO ENSURE THE FUTURE DEMAND FOR BIOLOGICS CAN STILL BE DELIVERED BY INJECTABLES
Anthony Vico and Enrico Barichello discuss the demands that high-viscosity biologic formulations place on prefilled syringes, and how pharmaceutical companies can make the most of this growing market segment to deliver improved quality of life for patients.
THE ADDED VALUE OF A PLATFORM APPROACH: PEN INJECTOR CASE STUDY
INJECTION
Dr Radoslaw Romanczuk
Nemera
THE ADDED VALUE OF A PLATFORM APPROACH: PEN INJECTOR CASE STUDY
Radosław Romańczuk, Severine Duband and Audrey Chandra discuss the development of the company’s pen-injector platforms and how they are tailored to meet the customer’s needs.
FORMULATION & DEVICE DEVELOPMENT: A SYMBIOTIC RELATIONSHIP
FORMULATION
Caroline Zakrzewski
Cambridge Design Partnership
FORMULATION & DEVICE DEVELOPMENT: A SYMBIOTIC RELATIONSHIP
Caroline Zakrzewski considers the interaction between formulation and device development and the challenges that drive innovation in the field. Her work frequently sits in the overlap between formulation and device development, navigating the interwoven steps that lead to the sweet spot, where formulation and a device work in tandem, providing safe and effective delivery of the drug.
PATIENT-CENTRICITY: THE IMPORTANCE OF HUMAN FACTORS IN THE PANDEMIC ERA
INJECTION
Asmita Khanolkar
SMC Ltd
PATIENT-CENTRICITY: THE IMPORTANCE OF HUMAN FACTORS IN THE PANDEMIC ERA
Marcus Agunloye and Asmita Khanolkar discuss how patient-centricity is at the heart of drug delivery device design and innovation, and how the global pandemic has highlighted the importance of patient-centric development in this field.
HOW OWEN MUMFORD CARRIED OUT USABILITY TESTING UNDER COVID-19 RESTRICTIONS
INJECTION
Miranda Newbery
HOW OWEN MUMFORD CARRIED OUT USABILITY TESTING UNDER COVID-19 RESTRICTIONS
Miranda Newbery describes working with Owen Mumford Pharmaceutical Services on usability testing for a platform autoinjector under covid-19 restrictions.
SAFE AND AUTOMATIC DEVICE TO IMPROVE DRUG PREPARATION FROM MULTIDOSE VIALS
INJECTION
Benjamin Morel
Eveon
SAFE AND AUTOMATIC DEVICE TO IMPROVE DRUG PREPARATION FROM MULTIDOSE VIALS
Benjamin Morel and Claire Authesserre discuss the challenges and opportunities presented by multidose vials.
RE-USABLE ELECTRONIC AUTOINJECTOR – FLEXIBLE PERFORMANCE
CONNECTIVITY
Bjarne Sørensen
Phillips Medisize
RE-USABLE ELECTRONIC AUTOINJECTOR – FLEXIBLE PERFORMANCE
Bjarne Sørensen discusses the ability of electronically driven injection devices to cater for a broad range of liquid drug properties within a single device platform.
ADDRESSING THE CHALLENGES OF VISCOUS INJECTABLE ADMINISTRATION
EXPERT VIEW
Dr Andrew Donnelly
ADDRESSING THE CHALLENGES OF VISCOUS INJECTABLE ADMINISTRATION
Andrew Donnelly and Shahid Uddin look at the challenges of self-administration of injectable viscous formulations and the technology that is helping to overcome these issues.
SUBCUJECT WBI: LOW-COST, LARGER VOLUME, HIGH-VISCOSITY WEARABLE BOLUS INJECTOR – USING STANDARD GLASS PRIMARY PACKAGING
WEARABLES
Claus Schmidt Moeller
SUBCUJECT WBI: LOW-COST, LARGER VOLUME, HIGH-VISCOSITY WEARABLE BOLUS INJECTOR – USING STANDARD GLASS PRIMARY PACKAGING
Claus Schmidt Moeller introduces the company’s wearable bolus injector for single use and discusses the advantages of the device.
OPHTHALMIC DRUGS: PATHWAY TO OVERCOME PRIMARY PACKAGING AND DRUG PRODUCT MANUFACTURING CHALLENGES
OCULAR
Rainer Glockler
ten23 health
OPHTHALMIC DRUGS: PATHWAY TO OVERCOME PRIMARY PACKAGING AND DRUG PRODUCT MANUFACTURING CHALLENGES
Rainer Glöckler, Carole Delauney, Dr Nicolas Eon and Katsuyuki Takeuchi discuss the myriad complexities of developing drug products for intravitreal injection, and how the partnership between swissfillon and Terumo can ease and accelerate these products to market. The first article, published in April, covered how swissfillon’s state-of-the-art filling line meets the complex requirements of ophthalmic drug products.
COMPARATIVE EXTRACTABLE STUDIES FOR INJECTABLES AND MEDICAL DEVICES ALIGNED WITH USP <1663> AND ISO 10993 GUIDELINES
INJECTION
Dr Matthias Bicker
SCHOTT Pharma
COMPARATIVE EXTRACTABLE STUDIES FOR INJECTABLES AND MEDICAL DEVICES ALIGNED WITH USP <1663> AND ISO 10993 GUIDELINES
Matthias Bicker, Michael Müller, Marc Mittermüller, Daniel Haines and Uwe Rothhaar discuss the regulatory requirements that need to be considered when designing an extractables and leachables study for a drug product or medical device. To illustrate the subject further, the authors provide two example studies, each following a different set of regulatory guidelines.
DRUG DELIVERY TO THE EYE: OVERCOMING THE CHALLENGES OF INTRAVITREAL PREFILLED SYRINGES
EXPERT VIEW
Dr Suresh Gupta
DRUG DELIVERY TO THE EYE: OVERCOMING THE CHALLENGES OF INTRAVITREAL PREFILLED SYRINGES
Suresh Gupta discusses the challenges of developing a PFS product for intravitreal injection, highlighting how designing for the intravitreal space, rather than the standard parenteral, imposes a number of additional requirements on the design.
HOSTAFORM<sup>®</sup> POM ECO-B – PROVEN, VERSATILE, EASY AND SUSTAINABLE
SUSTAINABILITY
Kevin Norfleet
Celanese
HOSTAFORM® POM ECO-B – PROVEN, VERSATILE, EASY AND SUSTAINABLE
Kevin Norfleet and Rob Haley discuss the need for environmentally sustainable materials in the medical device industry, and how Celanese’s Hostaform® MT® POM ECO-B meets that need, being an exact equivalent to the company’s existing material but produced using up to 97% bio-content using a potential greenhouse gas as feedstock, accounted for using the mass balance approach.
I-PLATFORM DEVICE: THE SMART DEVICE WITH APTITUDE
INJECTION
Jimmy Fan
CC Bio
I-PLATFORM DEVICE: THE SMART DEVICE WITH APTITUDE
Jimmy Fan outlines the capabilities and benefits of the I-Platform smart drug delivery device.
SURFACE-MEDIATED AGGREGATION – CONTROL OF THE LIQUID-SOLID INTERFACIAL STRESS
PREFILLED SYRINGES
Dr Shane Smith
Glycome BioPharma
SURFACE-MEDIATED AGGREGATION – CONTROL OF THE LIQUID-SOLID INTERFACIAL STRESS
Shane Smith, Eoin Scanlan and Paula Colavita discuss how the company’s technology has evolved to create a stable and biocompatible coating that maintains device performance and safety.
INTERVIEW WITH BENJAMIN DIETIKER, WEIDMANN MEDICAL TECHNOLOGY
INTERVIEW
Benjamin Dietiker
INTERVIEW WITH BENJAMIN DIETIKER, WEIDMANN MEDICAL TECHNOLOGY
Benjamin Dietiker, Weidmann Medical Technology, talks with ONdrugDelivery about how the company has successfully implemented a growth strategy by focusing on key areas, plans for expansion, the effect of covid-19 on the business, and how the company differentiates itself from larger competitors by focusing on quality and service.
ROOM FOR INNOVATION?
EXPERT VIEW
Darren Mansell
ROOM FOR INNOVATION?
Darren Mansell examines US FDA guidance on biosimilar interchangeability and asks whether there is room for innovation.
CONSIDERATIONS FOR DEVICE SELECTION IN PARENTERAL APPLICATIONS
INJECTION
Mark Tunkel
Nemera
CONSIDERATIONS FOR DEVICE SELECTION IN PARENTERAL APPLICATIONS
Mark Tunkel looks at the challenges involved in the selection of drug devices for combination products and the optimisation of the development process.
Top